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Abstract
To evaluate the relevance of fragile histidine triad (FHIT )
status in relation to drug treatment, we analyzed the
sensitivity of the Fhit-negative non–small cell lung
cancer (NSCLC) cell line NCI-H460 to different drugs,
after treatmentwith an adenoviral vector expressing the
FHIT transgene. Expression of Fhit resulted in reduced
sensitivity to etoposide, doxorubicin, and topotecan.
This feature was associated with Fhit-induced down-
regulation of DNA topoisomerases I and II. In contrast,
expression of Fhit did not modulate sensitivity to Taxol,
but produced a slight increase in sensitivity to cis-
platin, as shown by colony-forming assays. Analysis of
apoptosis revealed that, after cisplatin exposure, the
number of apoptotic cells was two-fold higher in Fhit-
expressing H460 cells. Moreover, it appeared that wild-
type p53 was required for sensitization to cisplatin
because the effect was marginal in A549 and Calu-1
cells, where the p53 pathway is altered and simulta-
neous restoration of p53 and Fhit in Calu-1 cells in-
creased cisplatin sensitivity. Fhit could also partially
restore sensitivity to cisplatin in Bcl-2– and Bcl-xL–
overexpressing H460 cells that are normally resistant
to this drug. Our results support the possible relevance
of FHIT in cisplatin-based chemotherapy as well as in
the reversal of drug resistance in NSCLC.
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Introduction
A major limitation to the curative potential of current chemo-
therapy is that many types of cancer, including lung cancer,
are resistant to apoptotic stimuli of various antitumor agents
and become progressively incurable [1,2]. The most effec-
tive chemotherapy for non–small cell lung cancer (NSCLC),
the leading cause of death among human malignancies,
has been cisplatin-based combination therapy for more
than two decades; however, long-term survival rate remains
unsatisfactory [3,4]. Understanding the molecular mecha-
nism of apoptosis and the events that cause resistance to
anticancer drugs is therefore crucial to developing new
strategies for the therapeutic treatment of lung cancer, with
the possibility of activating distinct or overlapping apoptotic
pathways by combining different treatments to increase anti-
tumor effects.
The tumor-suppressor gene FHIT, a member of the histidine
triad gene family, might be a promising candidate for NSCLC
therapy. The inactivation of Fhit protein is one of the earliest
events in different types of human malignancies, including lung
[5], esophageal [6], gastric [7], breast [8], and head and neck
[9] tumors. Previous studies showed that the reintroduction
of FHIT gene at low levels of expression in Fhit-negative lung
cancer cell lines reduces cell proliferation and alters cell cycle
profile, causing a G0/G1 arrest in a dose-dependent manner
[10], whereas high levels of Fhit expression are required to
efficiently induce apoptosis and to suppress tumorigenesis
in vivo [11]. Furthermore, homozygous and heterozygous FHIT
knockout mice exhibit high susceptibility to chemical carcino-
gens that can be prevented by treatment with Ad-Fhit, a Fhit-
expressing adenoviral vector [12,13].
In the present study, to explore whether Fhit could modulate
cell response to antitumor drugs, we used adenoviral-mediated
gene transfer to restore Fhit expression in Fhit-negative lung
cancer cells. We have previously reported that Fhit-induced
apoptosis was associated with activation of the caspase-8
pathway and that Fhit-reexpressing cells were highly sensitive
to external stimuli such as serum deprivation or Fas ligand
treatment, suggesting an involvement of Fhit in regulating the
apoptotic pathway at the cytoplasmic level [11]. In addition,
by engineering various NSCLC cell lines to express different
genes involved in apoptosis, we found that the apoptotic path-
way triggered by Fhit is dependent on cytoplasmic mediators,
whereas it is independent of mitochondrial mediators such
as Bcl-2 and Bcl-xL. Nonetheless, early activation of caspase-8
leads to subsequent cleavage of Bid, promoting a connection
between cytoplasmic and mitochondrial pathways to amplify
the initial apoptotic stimulus mediated by caspase-8 [14].
Abbreviations: FHIT, fragile histidine triad; NSCLC, non – small cell lung cancer; MOI,
multiplicity of infection; SRB, sulforhodamine B; TUNEL, TdT-mediated dUTP nick end labeling
Address all correspondence to: L. Roz, Department of Experimental Oncology, Istituto
Nazionale Tumori, Via Venezian 1, Milan 20133, Italy. E-mail: luca.roz@istitutotumori.mi.it
1This work was partially supported by grants from the Associazione Italiana per la Ricerca sul
Cancro (AIRC) and the Fondazione Ermenegildo Zegna and Fenera holding. F.A. and L.R.
were recipients of fellowships from AIRC.
2G. Sozzi and L. Roz contributed equally as senior coauthors.
Received 5 August 2005; Revised 20 October 2005; Accepted 21 October 2005.
Copyright D 2005 Neoplasia Press, Inc. All rights reserved 1522-8002/05/$25.00
DOI 10.1593/neo.05517
Neoplasia . Vol. 8, No. 1, January 2006, pp. 9 – 17 9
www.neoplasia.com
RESEARCH ARTICLE
Thus, because several lines of evidence support the
notion that chemotherapeutic agents exert their action
through a mitochondrial apoptotic pathway [15], we evalu-
ated whether the FHIT gene is able to modulate the prop-
erties of antitumor drugs in NSCLC and we examined the
effects of the simultaneous stimulation of Fhit-mediated ex-
trinsic pathway and cisplatin-induced intrinsic pathway in
different Fhit-negative lung cancer cell lines derived from dif-
ferent histologic subtypes: H460 (large cell carcinoma), A549
(adenocarcinoma), and Calu-1 (squamous cell carcinoma).
Our data indicate that Fhit expression results in variable
modulation of sensitivity to antitumor drugs, which can be
explained at the molecular level with changes in drug target
expression (e.g. DNA topoisomerases) or with cooperation
between apoptotic pathways (e.g., cisplatin). The present
study provides rational bases to combine Ad-Fhit and cis-
platin to enhance apoptotic response in lung cancer cells.
Materials and Methods
Cell Lines
ThehumanNSCLCcell linesH460, A549, andCalu-1 used
in this study were purchased from ATCC (Manassas, VA).
Cells were cultured in RPMI 1640 supplemented with 10%
heat-inactivated fetal calf serum (Bio-Whittaker Europe,
Verviers, Belgium). As previously described [15] for the gen-
eration of stable transfectants, H460 cells were transfected
with 10 mg of pEFFLAGpGK DNA plasmid, in which Bcl-2 and
Bcl-xL were subcloned, using Superfect reagent (Qiagen,
Milan, Italy), and the selectionwasmadeusing concentrations
of puromycin (Sigma, St. Louis,MO) ranging from1 to 2 mg/ml.
Clones were tested by Western blot analysis for the expres-
sion of specific proteins. The ecdysone-inducible mammalian
expression system (Invitrogen) was used to generate Calu-1
cells, which conditionally express FHITand/or p53. The system
uses the steroid hormone ecdysone analogue Ponasterone
A (Pon A) to activate the expression of genes through a hete-
rodimeric nuclear receptor. Clones selected from antibiotic-
resistant cultures were tested for inducible p53 and FHIT
expression after a 24-hour treatment with 7.5 mM Pon A.
Drugs
Different drugs were prepared as follows: cisplatin (Plati-
nex; Bristol-Myers Squibb, New York, NY) was diluted in
saline; Taxol was dissolved in dimethylsulfoxide and diluted
in water; doxorubicin and topotecan (Hycamptin; Glaxo-
SmithKline, Verona, Italy) were dissolved in water and di-
luted in saline; etoposide (Vepesid; Bristol-Meyers Squibb)
was diluted in saline; and gemcitabine (Gemzar; Eli Lilly,
Florence, Italy) was dissolved in saline.
Preparation of Adenoviral Vectors
The preparation of recombinant (E1- and E3-deleted)
adenoviral vectors expressing the Fhit protein was performed
in fetal kidney 293 cells (Microbix Biosystems, Inc., Toronto,
Canada) using standard techniques, as described previously
[11]. For Ad-Fhit, a 707-bp fragment of FHIT cDNA was
amplified by reverse transcription–polymerase chain reac-
tion (RT-PCR) from human placental cDNA and cloned into
an adenoviral shuttle vector (pQBI-AdCMV5) purchased from
Qbiogene (Montreal, Canada). The adenovirus expressing
LacZ (Ad-LacZ) protein was used as a control vector.
Western Blot Analysis
Western blot analysis was performed using standard
techniques. From each sample, 25 mg of proteins lysates
was separated on 8% to 15% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis and electroblotted onto poly-
vinylidene difluoride membranes (Amersham Biosciences,
Milan, Italy). Subsequently, membranes were incubated for
1 hour at room temperature in phosphate-buffered saline
(PBS)–Tween supplemented with 5% nonfat dry milk. For
immunodetection, the following antibodies were used: anti-
Fhit polyclonal antibody 71-9000 (1:1000; Zymed, San Fran-
cisco, CA); anti–Bcl-2 monoclonal antibody clone 120 (1:250;
Dako, Santa Barbara, CA); anti–Bcl-xL polyclonal antibody
(1:1000; BD Pharmingen, San Diego, CA); topoisomerase I
(1:500; BD Pharmingen); and topoisomerase IIa (1:500; Neo-
markers, Fremont, CA). As controls, actin (1:5000; Sigma) and
vinculin (1:100; Sigma) were used.
Sulforhodamine B (SRB) Assay
Cellular sensitivity to drugs of different classes was ex-
amined using the SRB assay [16]. Briefly, cells were treated
with Ad-Fhit and Ad-LacZ for 48 hours and then harvested
and seeded in 96-well microplates. Preliminary experiments
were performed to determine the appropriate cell seeding
number (H460 Ad-LacZ/H460 Ad-Fhit, 4000:6000 cells/well,
respectively) after confirming the linear relationship between
absorbance and the number of cells in the growth curve of
each cell line. Cells were treated for 48 hours with cisplatin,
Taxol, doxorubicin, etoposide, topotecan, or gemcitabine.
The cells were fixed by adding cold trichloric acetic acid to
medium. Plates were washed with spring water and air-dried,
and SRB solution was added for 30 minutes. The plates were
washed with 1% acetic acid, and cell-associated SRB was
solubilized using 10 mM Tris (pH 10.5) [17]. IC50 is defined as
the drug concentration causing a 50% decrease of absor-
bance at 550 nm over that of untreated control.
Colony-Forming Assay
Cell sensitivity to cisplatin was assessed by colony-
forming assay, as previously described [17]. Cells were
transduced with Ad-Fhit and Ad-LacZ constructs at a multi-
plicity of infection (MOI) = 5. Because Ad-Fhit infection alone
resulted in a reduced number of outgrowing colonies com-
pared with Ad-LacZ infection, 24 hours later, cells were har-
vested and seeded in 60-mm plates in triplicate (500 cells/
dish for Ad-LacZ, and 1000 cells/dish for Ad-Fhit–transduced
cells). After 24 hours, cells were exposed to 0.1 to 10 mM
cisplatin for 1 hour or 24 hours. When the drug was removed,
the cells were washed with saline and then incubated in drug-
free medium until colonies in control samples have become
evident (approximately 10 days later). Samples were stained
with 1% crystal violet in methanol for 1 hour, and colonies of
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at least 30 cells were counted using an inverse microscope.
IC50 is defined as the drug concentration producing a 50%
decrease in cell survival.
TdT-Mediated dUTP Nick End Labeling (TUNEL) Assay
Analysis of apoptosis was performed using TUNEL. Cells
were plated at 2  105 to 4  105 cells/six-well plate. On the
following day, adenoviral vectors were added at an MOI = 5
in 1 ml of culture medium without serum. After 4 hours, fresh
medium was added. Cisplatin treatment was performed
24 hours postinfection, and then the cells were cultured 24 to
48 hours before analysis. A total of 5  105 cells per sample
were fixed with 2% paraformaldehyde in PBS (10 minutes
on ice), washed three times with Tris-buffered saline (TBS;
50 mM Tris–HCl in saline solution, pH 7.5), permeabilized
with ice-cold acetone (2 minutes on ice), and washed twice in
TBS and once in distilled water. Staining was performed by
incubating cells for 1 hour at 37jC in 30 ml (final volume) of
TUNEL reaction mixture (In Situ Cell Death Detection Kit,
Fluorescein; Roche, Milan, Italy). Cells with fragmented DNA
display increased fluorescence, as measured using FACS-
CALIBUR flowcytometer (BD Biosciences, San Jose, CA).
Apoptotic cells were defined based on negative controls
represented by noninfected cells, cells infected with control
adenoviruses (Ad-LacZ), and cells treated with TUNEL reac-
tion mixture without the enzyme.
Quantitative Real-Time PCR
To evaluate the expression level of p21Waf1 mRNA in
H460 infected with Ad-Fhit and Ad-LacZ and treated with
cisplatin, quantitative real-timeRT-PCRwas performed. Total
RNA (500 ng) from cells untreated or treated with cisplatin for
1 hour and then collected at different time points was reverse-
transcribed. cDNA was then diluted 10 times, and 1 ml of the
diluted sample was used in the PCR reaction performed
with ready-to-use p21Waf1 Assay-on-Demand (Applied Bio-
systems, Milan, Italy). Hypoxanthine–guanine phosphoribosyl
transferase was used as endogenous control for the nor-
malization of different samples and for relative quantization of
gene expression; the data were analyzed by comparative Ct
method (DDCt).
Results
Experimental Models
Adenoviral-mediated FHIT gene transfer was used to
transduce the Fhit-negative NSCLC cell line H460. Cells
were infected at an MOI = 5, and an adenoviral vector ex-
pressing the LacZ gene was used in all experiments as a
control for possible alterations due to viral infection. In the
experiments described below, we used experimental condi-
tions under which 70% to 90%of target cells were transduced
in the absence of vector-induced cytotoxicity. Our analysis
included the parental H460 cell line as well as H460 clones
stably transfected with antiapoptotic molecules Bcl-2 and
Bcl-xL, which have been reported as a major determinant of
resistance to anticancer agents [18,19]. Western blot analy-
sis showed that Fhit protein expression was already detect-
able at 24 hours postinfection, increased at 36 hours, and
then remained stable (Figure 1A). All cells were efficiently
transduced and equally susceptible to adenoviral infection,
as demonstrated byWestern blot analysis (Figure 1B) and by
a similar percentage of positive b-gal cells after infection with
a control adenoviral vector carrying the LacZ reporter gene.
Cellular Sensitivity of Ad-Fhit– Infected Cells to Antitumor
Drugs of Different Classes
To define whether restoration of Fhit expression resulted
in changes in cellular sensitivity to antitumor drugs of differ-
ent classes, we used the SRB assay. H460 cells were
infected with Ad-Fhit and Ad-LacZ at an MOI = 5. Cells were
harvested 48 hours later and seeded in microtiter plates.
Cells were treated for 48 hours with different concen-
trations of drugs, which act through different mechanisms
of action (i.e., cisplatin, Taxol, etoposide, doxorubicin, gem-
citabine, or topotecan). As shown in Figure 2, we found
that adenovirus-mediated FHIT gene transfer resulted in re-
duced sensitivity to etoposide, doxorubicin, topotecan, and
gemcitabine, but not to Taxol. Slightly increased sensitivity to
cisplatin was observed with an IC50 = 2.2 mM for cells treated
with Ad-Fhit compared to IC50 = 3.8 mM for cells treated
with Ad-LacZ.
DNA Topoisomerase Levels in Ad-Fhit– Infected Cells
Because resistance to DNA topoisomerase I and II inhib-
itors has been associated with reduced levels of target
[20,21], we performed a Western blot analysis of Ad-Fhit–
infected cells to examine the modulation of topoisomerase
expression. We found that expression of Fhit was associated
with a decrease in topoisomerase II and I levels compared
with Ad-LacZ–infected cells, with the extent being higher for
the former enzyme (Figure 3).
Figure 1. Western blot analysis of Fhit expression in different cell systems.
(A) Analysis of Fhit expression in Ad-Fhit – transduced NSCLC cells. H460
cells were infected at an MOI = 5 for Ad-Fhit, and Fhit expression was
analyzed at different time points. The Fhit protein is already detectable at
24 hours, increases at 36 hours, and then remains stable. (B) Levels of ex-
pression of the Fhit protein in H460 clones stably transfected with the anti-
apoptotic proteins Bcl-2 and Bcl-xL.
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H460 Sensitivity to Cisplatin Assessed by
Colony-Forming Assay
Because cisplatin is commonly used in the treatment of
lung cancer, we performed further experiments to investi-
gate whether the differences in sensitivity observed using
the growth inhibition assay after combined treatment with
cisplatin and Ad-Fhit were still evident using a clonogenic
assay, which measures the long-term survival of tumor cells.
The cells were infected with either Ad-Fhit or Ad-LacZ at
an MOI = 5; after 24 hours, they were treated with different
concentrations of cisplatin for 1 hour and then were tested for
clonogenic potential. As shown in Figure 4A, reexpression
of Fhit was associated with an increased sensitivity to cis-
platin, with IC50 = 9.1 mM for cells treated with Ad-Fhit and
with IC50 = 43 mM for cells treated with Ad-LacZ. Thus, Ad-
Fhit cooperated with cisplatin to reduce the clonogenic sur-
vival of tumor cells.
Previous studies have already reported the involvement
of Fhit in cell growth control through increased expression
levels of p21Waf1, a cell cycle regulator that binds and inhibits
the activity of cyclin-dependent kinases [22]. To elucidate the
molecular mechanisms underlying sensitization to cisplatin
in H460 cells after FHIT gene transfer, we performed a real-
time PCR to evaluate the levels of p21Waf1 transcript. H460
cells were infected with either Ad-Fhit and Ad-LacZ; after
24 hours, the cells were treated with cisplatin for 1 hour. The
drug was removed; 6 and 20 hours later, cells were collected
to evaluate the levels of p21Waf1. Real-time PCR analysis
(Figure 4B) showed an increase of p21Waf1 transcript levels
in Ad-Fhit– treated cells compared to controls (Ad-LacZ),
suggesting that the synergistic effect between Fhit and
cisplatin could be mediated by p21Waf1. The modulation of
p21Waf1 transcript reflected changes also at protein levels
because slightly higher levels of p21Waf1 protein were found
        
       
 
  
      
     
 
  
     
     
   
 
  
     
 
  
     
       
  
 
  
Figure 2. Effect of Fhit expression on the sensitivity of H460 cell line to different antitumor drugs. Cell sensitivity was assessed by SRB assay after a 48-hour drug
exposure. H460 cells were infected with Ad-Fhit and Ad-LacZ as controls at an MOI = 5 and were harvested 48 hours later. Cells were then seeded and exposed to
drugs at indicated doses for 2 days. IC50 = concentration of a drug required to reduce absorbance by 50% at 550 nm.
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in H460 cells under the combined Ad-Fhit and cisplatin
treatment after 20 hours (Figure 4C). Recently, a synergistic
oncosuppressive effect between Fhit and p53 has been re-
ported. It has been suggested that this might be due to
stabilization of p53, which is related to Fhit-mediated down-
regulation of MDM2 [23]. In our experimental conditions, we
did not observe a change in p53 levels (data not shown);
therefore, it seems more plausible that the higher sensitivity
to cisplatin in Fhit-reexpressing cells might be explained by
a convergence of the two pathways on a common mediator
represented by p21Waf1.
Cisplatin-Induced Apoptosis in Ad-Fhit–Transduced Cells
We have previously demonstrated that apoptosis induced
by Fhit reexpression is modulated by a caspase-8–mediated
cytoplasmic pathway, whereas cisplatin-induced apoptosis
requires amplification by mitochondria for the activation of a
downstream effector system [14]. Therefore, we performed
an analysis of apoptosis induction using the TUNEL assay in
H460 cells treated with cisplatin after transduction with Ad-
Fhit or control Ad-LacZ. We used experimental conditions
under which the infection rate was close to 70% without any
cytotoxic effect induced by the vectors. The cells were then
treated with 10 mM cisplatin, and TUNEL analysis was per-
formed 24 or 48 hours after drug exposure. In the repre-
sentative experiment shown, we found that, 24 hours after
cisplatin exposure, the percentage of apoptotic cells was
18% in Ad-Fhit– infected cells compared to 14% in Ad-
LacZ–infected cells and 9% in uninfected controls. TUNEL
analysis performed 48 hours after cisplatin exposure re-
vealed a marked difference in sensitivity, with the number
of apoptotic cells being 40% in Ad-Fhit– infected cells, 19%
in Ad-LacZ–infected cells, and 15% in uninfected controls
(Figure 5). These data support the notion that restoration of
Fhit protein in the Fhit-negative H460 cell line leads to an
increased susceptibility to cisplatin through an enhancement
at the apoptosis level.
Effect of Ad-Fhit and Cisplatin Combination Treatment
on Cisplatin-Resistant Clones
Bcl-2 and Bcl-xL are two important members of a family
of proteins responsible for deregulation of apoptosis and
prevention of death in cancer cells [24]. Their overexpression
has been associated with cellular resistance to antitumor
drugs [18,19]. H460 cells overexpressing Bcl-2 and Bcl-xL
that were protected from cisplatin cytotoxicity remain sensi-
tive to Fhit-induced apoptosis, thereby indicating that mito-
chondrial amplification is not required for Fhit activity [14]. To
evaluate whether combined treatment with Ad-Fhit and
cisplatin may result in a cooperative effect also in Bcl-2 and
Bcl-xL H460-overexpressing cells, we examined clonogenic
survival and apoptosis levels in these clones.
The clones overexpressing Bcl-2 and Bcl-xL were treated
with Ad-Fhit, Ad-LacZ, or medium alone for 24 hours at an
MOI = 5; under these conditions, the vectors did not show
significant cytotoxicity. Transduced cells were then exposed
to cisplatin for 1 hour. As shown in Figure 6A, the combination
  
 
 
   
 
 
 
        
Figure 4. Antiproliferative effect of Ad-Fhit and cisplatin treatment. (A)
Clonogenic survival of cisplatin-treated H460 cell line. H460 cells were infected
with Ad-LacZ or Ad-Fhit for 24 hours and then treated with cisplatin for 1 hour
before performing colony-forming assay. (B and C) Modulation of p21Waf1
expression. H460 cells were infected with Ad-Fhit and Ad-LacZ for 24 hours
and treated with cisplatin. One hour later, the drug was removed; after 6 and
20 hours, p21Waf1 mRNA levels were assayed by real-time PCR (B). p21Waf1
protein expression was analyzed by Western blot analysis (C).
Figure 3. Western blot analysis of topoisomerase I and IIa expression. H460
cells were infected with an MOI = 5 of Ad-Fhit and Ad-LacZ, or treated with
medium. The expression of Fhit was associated with a decrease in topo-
isomerase protein expression levels, which was more evident in topo-
isomerase IIa. Vinculin was used as a control.
Sensitization to Cisplatin after FHIT Gene Transfer Andriani et al. 13
Neoplasia . Vol. 8, No. 1, 2006
of Ad-Fhit and cisplatin moderately reduced colony forma-
tion, with the IC50 of Bcl-2–overexpressing cells transduced
with Ad-Fhit being 2.07 mM and of cells transduced with Ad-
LacZ being 4.21 mM. The effect was even less marked in Bcl-
xL–overexpressing cells. Thus, the extent of modulation was
less significant when compared to those obtained in the
H460 parental cell line, probably due to the effect of Bcl-2
and Bcl-xL antiapoptotic molecules. We then evaluated the
cooperation of cisplatin and Ad-Fhit to induce apoptosis in
these clones by TUNEL assay. Cells were transduced with
Ad-Fhit and Ad-LacZ for 24 hours at an MOI = 5 and treated
with 16 mM cisplatin for 24 hours. Under these experimental
conditions, the rate of apoptotic cells after Ad-Fhit/cisplatin
combination was 34% in the Bcl-2–expressing clone and 28%
in the Bcl-xL–expressing clone, compared with the Ad-LacZ/
cisplatin combination that showed 6% and 16% of apoptotic
cells. Cisplatin alone resulted in only 1% and 6% of apoptotic
cells in Bcl-2 andBcl-xL clones, respectively (Figure 6B). Thus,
the combined treatment of Ad-Fhit and cisplatin was more
effective in inducing cytotoxic effects compared with the
combination treatment of cisplatin and Ad-LacZ, or with treat-
ment with cisplatin alone, even in Bcl-2– or Bcl-xL–over-
expressing clones.
Effect of Ad-Fhit and Cisplatin Combination Treatment
on A549 and Calu-1 Cell Lines
To further evaluate the possibility that sensitivity to cis-
platin is modified by treatment with Ad-Fhit also in cell lines
derived from other histologic subtypes of NSCLC, we ex-
tended our analyses to the A549 cell line (adenocarcinoma)
and the Calu-1 cell line (squamous cell carcinoma). The
A549 cell line was infected with Ad-Fhit and Ad-LacZ at
an MOI = 5 for 24 hours and then treated with different con-
centrations of cisplatin for 24 hours. The results of the clo-
nogenic assay are shown in Figure 7A. The value of IC50 in
the A549 cell line was 17.8 mM for cells infected with Ad-Fhit
and 23.4 mM for cells infected with Ad-LacZ, indicating no
significant effect on sensitivity when compared to those
observed in the H460 cell line.
To evaluate whether the combined effect of Ad-Fhit
and cisplatin results in an increased apoptotic response,
we performed a TUNEL assay in the A549 and Calu-1 cell
lines. Cells were transduced with Ad-Fhit and Ad-LacZ, or
  
  
 
 
Figure 6. Effect of combination treatment with cisplatin and Ad-Fhit on Bcl-2 – and Bcl-xL –overexpressing clones. (A) Clonogenic survival. Cells were infected with
Ad-Fhit and Ad-LacZ for 24 hours at an MOI = 5 and were then exposed to cisplatin for 1 hour before clonogenic survival analysis. (B) Apoptosis analysis. Cells
were transduced with Ad-Fhit and Ad-LacZ for 24 hours at an MOI = 5 and then treated with 16 M cisplatin for 24 hours. The presence of apoptotic cells was
assessed by TUNEL assay, and the experiment is representative of assays, performed at least three times, that gave comparable results.
Figure 5. Apoptosis analysis. H460 cells were transduced with Ad-Fhit and
Ad-LacZ at an MOI = 5, or treated with medium for 24 hours and then ex-
posed to 10 M cisplatin for 24 and 48 hours. Apoptosis was determined by
TUNEL assay. The experiment is representative of assays, performed at
least three times, that gave comparable results.
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incubated with the medium for 24 hours. Under these con-
ditions, the expression of Fhit protein was robust without any
toxic effects. The A549 and Calu-1 cells were then treated
with 32 and 64 mM cisplatin, respectively, and apoptosis was
analyzed 24 hours after drug exposure. A slightly increased
level of cisplatin-induced apoptosis was found in A549 cells,
with a rate of apoptotic cells higher in Ad-Fhit– infected cells
compared to that in Ad-LacZ–infected cells or untreated
cells. No effects were observed in the Calu-1 cell line, where
the combination of Ad-Fhit and cisplatin did not show a dif-
ferent apoptotic response when compared with the controls
(Figure 7B). An interesting possibility is that the different re-
sponse observed in the various cell lines could be related to
underlying differences in the p53 pathway in H460 (p53-wt),
A549 (p53-wt but ARF-null), and Calu-1 cells (p53-null).
To determine whether p53 status plays a role in modulat-
ing sensitivity to cisplatin in the presence of the FHIT gene,
the Calu-1 cell line, which lacks the expression of FHIT and
p53, was stably transfected with hormone-inducible vectors
that allowed a tight modulation of transgene expression. The
effect of the simultaneous restoration of Fhit and p53 on
sensitivity to cisplatin was evaluated by comparing Calu-1
cells induced to express Fhit or p53 alone. Different cells
were treated with 10 mM Pon A for 24 hours to activate
transgene expression; 24 hours later, 64 mM cisplatin was
added to assess the sensitivity to the drug. Apoptosis was
analyzed 24 hours after drug exposure by TUNEL assay. Dif-
ferent levels of cisplatin-induced apoptosis were found, with
the rate of apoptotic cells being higher in Calu-1 cells ex-
pressing both p53 and Fhit, compared with cells expressing
either Fhit or p53. As expected, restoration of p53 alone also
resulted in increased sensitivity but at lower levels compared
to the expression of both genes. The results support the
relationship of p53 gene status and sensitization to cisplatin in
Fhit-expressing cells.
Discussion
Combination therapies have been shown to produce a
response rate that is higher than those obtained with
single-agent chemotherapy in many types of cancer, includ-
ing NSCLC. However, the success of therapies is limited, and
one of the reasons for this limitation is drug resistance. Be-
cause only a minority of patients survive for more than a year
after treatment, new agents and novel approaches are needed
to improve the response to conventional therapies in NSCLC
patients [25]. Apoptosis has been regarded as a process that
could be targeted for tumor cell killing because inadequacy
in executing apoptotic programs has been associated with
resistance to antitumor drugs [24]. Two major apoptotic path-
ways originating from different subcellular compartments
have been identified (i.e., the extrinsic or receptor-mediated
pathway, generated at the level of the cytoplasmic membrane,
following the interaction of death receptors with their ligands,
and the intrinsic or mitochondrial pathway originating from
the mitochondria, whose impairment is induced by proapop-
totic Bcl-2 family members) [26]. Recent studies have demon-
strated that the overexpression of the FHIT gene in NSCLC
by an adenoviral vector resulted in growth inhibition and in-
creased apoptotic response in the presence of external apop-
totic stimuli [11]. Furthermore, studies on H460 and other
NSCLC cell lines overexpressing different molecules essential
for apoptotic cascade delineated clearer evidence on the Fhit
mechanism of action, which appears to be primarily mediated
by caspase-8 activation rather than by mitochondrial me-
diators of apoptosis such as Bcl-2 and Bcl-xL [15]. On the
           
Figure 7. Sensitivity of A549 and Calu-1 cell lines to a combination treatment
of cisplatin and Ad-Fhit. (A) Clonogenic survival in A549 cell line. A549 cells
were infected with Ad-Fhit and Ad-LacZ at an MOI = 5 for 24 hours and then
treated with different doses of cisplatin for 24 hours. (B) Apoptosis analysis in
A549 and Calu-1 cell lines. Cells were infected with Ad-Fhit and Ad-LacZ or
treated with medium as control for 24 hours and then treated with 32 and
64 M cisplatin, respectively, for 24 hours. Results are expressed as per-
centages of apoptotic cells relative to medium-treated cells and represent the
mean of three different independent analyses. (C) Calu-1 cells expressing in-
ducible Fhit, p53, or both were incubated in the absence or in the presence of
Pon A to induce transgene expression. After 24 hours, the cells were treated
with 64 M cisplatin for 24 hours, and the presence of apoptotic cells was
assessed by TUNEL assay. The results are expressed as percentages of
apoptotic cells relative to controls, represented by uninduced cells.
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other hand, some antitumor agents, including cisplatin, lead
to cell death and cell cycle arrest through the formation of
DNA lesions, which activate multiple pathways involving the
mitochondria and p53 [3]. Based on this background, we
investigated whether the simultaneous stimulation of the ex-
trinsic pathway through Fhit transduction and of the intrinsic
pathway using a cytotoxic agent (i.e., cisplatin) may result in
increased cell death in NSCLC cell lines. A relevant finding of
the present study is that FHIT gene transfer increases the
sensitivity to cisplatin in NSCLC and that the pathways trig-
gered by Fhit and cisplatin appear to cooperate in H460 cells
with a mechanism underlying synergistic antiproliferative ac-
tivity involving p21Waf1 upregulation. It has recently been
suggested that Fhit can regulate p53 levels [23]; however,
the fact that previous studies have shown that the oncosup-
pressive properties of Fhit and its ability to regulate p21Waf1 are
p53-independent [10,27] and that we did not observe any p53
regulation in our system suggests that our results are due to a
convergence of the Fhit and cisplatin-triggered pathways on
p21Waf1 rather than on a Fhit-mediated increase in p53 levels.
Sensitization to cisplatin by Fhit reexpression was evi-
dent when clonogenic survival and apoptosis were assayed,
whereas only a modest difference in IC50 values of Ad-LacZ–
and Ad-Fhit– infected cells was observed using the SRB as-
say, which measures the inhibition of growth in a short-term
assay. The apparent discrepancy between the former and the
latter techniques further supports that the modulation of cis-
platin sensitivity by Fhit occurs at the level of factors influenc-
ing survival and apoptotic cell death. Thus, a sufficient amount
of time for the cells to die after they have been damaged
by combined treatment with Ad-Fhit and cisplatin is critical.
Moreover, in this context, it appears that wild-type p53 is re-
quired for sensitization to cisplatin because the effect was evi-
dent in H460 cells (wild-type p53) and was marginal in A549
cells in which the p53 function is altered due to the loss of ARF
expression as a consequence of deletion or promoter methyl-
ation of the gene. This mechanism should result in a hyper-
active MDM2 expression and enhanced p53 degradation.
Again, no Fhit-mediated increase in cisplatin-induced apop-
tosis was observed in Calu-1 cells that carry a homozygous
deletion of the p53 gene [29]. Thus, a hormone-inducible ex-
pression system was considered as an appropriate approach
to clarify the effect of p53andFhit replacement on sensitization
to cisplatin in Calu-1 cells. Indeed, Calu-1 cells became more
sensitive to cisplatin-induced apoptosis on a regulated expres-
sion of p53 and Fhit obtained by the inducible system.
The increased sensitivity to cisplatin observed after ade-
noviral FHIT gene transfer in H460 cells was reduced in Bcl-
2– and Bcl-xL–overexpressing clones compared with H460
parental cells when measured using clonogenic assay. How-
ever, marked sensitization to cisplatin was observed in terms
of apoptosis. In fact, because the apoptotic mechanism
triggered by the Fhit protein has been shown to be indepen-
dent of mitochondrial mediators [14], we reasoned that res-
toration of Fhit could possibly modify the cisplatin sensitivity
of Bcl-2– and Bcl-xL–expressing cells, especially with re-
spect to apoptotic response. Colony-forming assay, on the
other hand, measures the long-term response to cytotoxic
stimuli [30]; under these experimental conditions (adenoviral
infections), it has to be considered that the expression of the
FHIT transgene is expected to decline over time (due to cell
division), possibly resulting in insufficient counteraction of
prosurvival signals (Bcl-2 and Bcl-xL). To further support this
interpretation, it is worth noting that the antiproliferative effect
of Fhit has recently been shown to be extremely dose-
dependent [10]. Apoptosis analysis was observed earlier
than clones in a clonogenic assay, and it is likely that the
results of the clonogenic assay also reflect the contribution of
other factors involved in cell survival to the regulation of drug
sensitivity. Most anticancer drugs act at the mitochondrial
level, but alterations in this pathway are frequent in tumors
and can negatively influence apoptotic response, leading to
resistance of tumors to therapy. On the contrary, in a recent
study, we showed that Fhit-induced apoptosis in H460 cells
was not inhibited by the overexpression of Bcl-2 and Bcl-xL
[14]. However, in those experiments, apoptosis was studied
in peculiar experimental conditions (i.e., high level of infection
in terms of MOI, days of infection, and serum starvation),
which are useful in understandingmolecular mechanisms but
not in modulating drug sensitivity. Thus, in the present study,
we maintained transduction levels of Fhit protein at around
60% to 70% to avoid vector toxicity, whereas sufficient ex-
pression levels of the Fhit protein were obtained. Our findings
provide evidence that Ad-Fhit used in experimental condi-
tions that usually do not cause apoptosis increased cell sensi-
tivity to cisplatin, producing a synergistic effect on apoptosis
in cells that are typically resistant to anticancer drugs.
An interesting observation of this study was the finding
that the reexpression of Fhit in H460 cells resulted in reduced
sensitivity to DNA topoisomerase I and II inhibitors and in no
influence on cell response to Taxol. The acquisition of
resistance to the abovementioned agents appeared depen-
dent on the fact that Fhit expression produced a decrease on
the level of target enzyme. The extent of downregulation is in
keeping with the degree of resistance observed after Fhit
expression. Indeed, resistance was higher in the case of
etoposide (five-fold) and doxorubicin (around 20-fold) than
for topotecan. The previously documented effect of Fhit on
the slowdown of proliferation [11] could also confer resis-
tance to DNA topoisomerase inhibitors and gemcitabine.
In conclusion, the therapeutic restoration of the FHIT
gene in NSCLC is capable of modulating sensitivity to cis-
platin in terms of colony formation and apoptosis in different
cell systems. We also demonstrate that this therapeutic
approach continues to be effective despite the overexpres-
sion of antiapoptotic molecules such as Bcl-2 and Bcl-xL.
Combination therapy of Ad-Fhit and cisplatin could provide
the basis for developing novel and effective therapeutic ap-
proaches that are able to enhance the efficacy of cisplatin-
based chemotherapy as well as to reverse drug resistance
in NSCLC.
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